Supernus Pharmaceuticals, Inc. (SUPN): Price and Financial Metrics


Supernus Pharmaceuticals, Inc. (SUPN): $26.82

-0.46 (-1.69%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

SUPN POWR Grades


  • Value is the dimension where SUPN ranks best; there it ranks ahead of 98.97% of US stocks.
  • SUPN's strongest trending metric is Growth; it's been moving down over the last 47 weeks.
  • SUPN's current lowest rank is in the Growth metric (where it is better than 6.1% of US stocks).

SUPN Stock Summary

  • Supernus Pharmaceuticals Inc's stock had its IPO on May 1, 2012, making it an older stock than 33.85% of US equities in our set.
  • Revenue growth over the past 12 months for Supernus Pharmaceuticals Inc comes in at 34.57%, a number that bests 80.38% of the US stocks we're tracking.
  • The volatility of Supernus Pharmaceuticals Inc's share price is greater than that of 33.32% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to SUPN, based on their financial statements, market capitalization, and price volatility, are SCL, BDC, SANW, VIVO, and CTS.
  • SUPN's SEC filings can be seen here. And to visit Supernus Pharmaceuticals Inc's official web site, go to www.supernus.com.

SUPN Valuation Summary

  • SUPN's price/sales ratio is 2.6; this is 31.58% lower than that of the median Healthcare stock.
  • SUPN's price/sales ratio has moved down 164 over the prior 114 months.
  • Over the past 114 months, SUPN's price/earnings ratio has gone up 11.9.

Below are key valuation metrics over time for SUPN.

Stock Date P/S P/B P/E EV/EBIT
SUPN 2021-08-31 2.6 1.9 14.6 10.4
SUPN 2021-08-30 2.5 1.8 14.0 10.0
SUPN 2021-08-27 2.5 1.8 14.0 10.0
SUPN 2021-08-26 2.3 1.7 13.3 9.6
SUPN 2021-08-25 2.4 1.7 13.5 9.7
SUPN 2021-08-24 2.3 1.7 13.3 9.6

SUPN Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at -4.39%.
  • Its 4 year revenue growth rate is now at 152.41%.
  • The year over year net cashflow from operations growth rate now stands at 39.17%.
SUPN's revenue has moved up $342,567,000 over the prior 52 months.

The table below shows SUPN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 570.953 120.006 100.185
2021-03-31 556.353 165.683 111.126
2020-12-31 520.397 138.399 126.95
2020-09-30 477.286 150.257 129.311
2020-06-30 424.291 182.316 118.174
2020-03-31 402.257 119.052 116.234

SUPN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SUPN has a Quality Grade of B, ranking ahead of 91.14% of graded US stocks.
  • SUPN's asset turnover comes in at 0.375 -- ranking 124th of 677 Pharmaceutical Products stocks.
  • RETA, LUMO, and PTCT are the stocks whose asset turnover ratios are most correlated with SUPN.

The table below shows SUPN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.375 0.860 0.164
2021-03-31 0.370 0.886 0.187
2020-12-31 0.366 0.899 0.196
2020-09-30 0.357 0.920 0.201
2020-06-30 0.343 0.949 0.173
2020-03-31 0.356 0.957 0.155

SUPN Price Target

For more insight on analysts targets of SUPN, see our SUPN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $35.00 Average Broker Recommendation 1.5 (Moderate Buy)

SUPN Stock Price Chart Interactive Chart >

Price chart for SUPN

SUPN Price/Volume Stats

Current price $26.82 52-week high $34.29
Prev. close $27.28 52-week low $17.20
Day low $26.63 Volume 419,587
Day high $27.22 Avg. volume 501,688
50-day MA $26.45 Dividend yield N/A
200-day MA $27.98 Market Cap 1.43B

Supernus Pharmaceuticals, Inc. (SUPN) Company Bio


Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company was founded in 2005 and is based in Rockville, Maryland.


SUPN Latest News Stream


Event/Time News Detail
Loading, please wait...

SUPN Latest Social Stream


Loading social stream, please wait...

View Full SUPN Social Stream

Latest SUPN News From Around the Web

Below are the latest news stories about Supernus Pharmaceuticals Inc that investors may wish to consider to help them evaluate SUPN as an investment opportunity.

Are Investors Undervaluing Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) By 49%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Supernus...

Yahoo | September 13, 2021

Novavax Stock Is Best Covid Vaccine Name To Speculate On

Novavax used a conventional technology to develop a vaccine, which has slowed development and approval.

Dana Blankenhorn on InvestorPlace | September 9, 2021

Supernus (SUPN) Seeks Label Expansion for ADHD Drug Qelbree

The FDA accepts Supernus' (SUPN) regulatory application seeking label application for Qelbree to include adult patients with ADHD.

Yahoo | September 3, 2021

Supernus to Participate in Upcoming September Investor Conferences

ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Companys management will participate and host investor meetings in the following upcoming September 2021 virtual investor conferences.

Intrado Digital Media | September 2, 2021

Supernus Announces Qelbree sNDA for Adult Indication Accepted for Review by FDA

ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has acknowledged it has received the supplemental new drug application (sNDA) for Qelbree (viloxazine extended-release capsules) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adult patients. The sNDA is now considered filed, with a user fee goal date (PDUFA date) of April 29, 2022.

Intrado Digital Media | September 2, 2021

Read More 'SUPN' Stories Here

SUPN Price Returns

1-mo 11.33%
3-mo -17.48%
6-mo 6.64%
1-year 20.00%
3-year -45.15%
5-year 2.72%
YTD 6.60%
2020 6.07%
2019 -28.60%
2018 -16.64%
2017 57.82%
2016 87.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8789 seconds.